Uncategorized

China’s industrial inspection landscape is undergoing a fundamental shift. The country is deploying inspection robots at scale across power grids, pipeline networks, and high-risk industrial sites. This is not a pilot phase or a future projection. It is happening now, with measurable results in efficiency, safety, and data intelligence. The numbers tell the story. In

Jinko Solar is one of China’s largest vertically integrated photovoltaic manufacturers and the first supplier to report more than 400 GW of cumulative module deliveries. Its position rests on manufacturing scale, rapid commercialization of N-type TOPCon technology, and a sales network built around major solar markets.  The company matters because it shows how China converts

China’s robotics race is moving from demonstrations toward repeatable work in factories, warehouses, infrastructure, and service environments. That shift raises the value of robot sensors. A robot can only act reliably when it can locate objects, estimate depth, detect contact, measure force, identify hazards, and interpret change. The opportunity now lies at the intersection of

The leading solar panel manufacturers in China include JinkoSolar, LONGi, Trinasolar, JA Solar, Tongwei, Astronergy, and Risen Energy. Yet the best supplier depends on the project. TOPCon leaders compete on scale and cost, HJT specialists target high bifaciality and hot-climate performance, while back-contact producers prioritize power density.  China added 315 GW of solar capacity in

LONGi is a Xi’an-headquartered Chinese solar technology company with major positions in monocrystalline wafers, cells, modules, and energy solutions. Its importance comes from the combination of production scale and a concentrated bet on back-contact technology. In 2025, the company shipped 111.56 GW of wafers and 86.58 GW of modules, including 22.87 GW of BC modules.

China’s rehabilitation sector is becoming a serious test bed for intelligent physical therapy. Exoskeleton rehabilitation now sits at the intersection of medical robotics, elder care, stroke rehabilitation, patient mobility, community health, and embodied intelligence. The timing matters.  China ended 2025 with 323.38 million people aged 60 or above, equal to 23 percent of the population.

China’s surgical robotics sector entered a more demanding phase. Product approvals still matter, but the harder tests now concern hospital use, service capacity, payment, clinical training, and overseas expansion. The Toumai Surgical Robot, developed by Shanghai MicroPort MedBot, has become one of the clearest examples of this shift. Toumai moved beyond a domestic localization story

China’s medical robots sector is entering a more commercially disciplined phase. Product approval still matters, but hospitals now look closely at clinical value, physician training, service pricing, workflow integration, safety evidence, and long-term operating costs. The policy framework is also becoming clearer. In July 2025, China’s National Medical Products Administration announced plans to develop classification

China’s market for surgical robots has entered a decisive commercial phase. Hospitals are no longer evaluating these systems mainly as experimental technology. Purchasing decisions now center on clinical value, approved indications, surgeon training, system reliability, instrument costs, and local technical support. Public tender activity offers a useful view of this shift. According to MedChina’s analysis

The map of China’s new energy vehicle manufacturing is being redrawn. While Shenzhen, Shanghai, and Hefei have long dominated the conversation, a quieter but more formidable force has emerged in central Zhejiang. Jinhua, China, has transformed from a traditional manufacturing hub into one of the country’s most dynamic NEV industrial clusters.  The 2025 numbers are